{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:05:53Z","timestamp":1761901553561,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008361","name":"Scleroseforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.msard.2020.102281","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T21:04:50Z","timestamp":1591823090000},"page":"102281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13"],"prefix":"10.1016","volume":"44","author":[{"given":"M.N.","family":"Olesen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.C.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pihl-Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.K.","family":"Soelberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.A.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Brandslund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.T.","family":"Lillevang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.S.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8551-0947","authenticated-orcid":false,"given":"N.","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102281_bib0001","first-page":"1204","volume":"19","author":"Alvarez","year":"2013"},{"key":"10.1016\/j.msard.2020.102281_bib0002","article-title":"Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures","volume":"1","author":"Alvarez","year":"2015","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"4","key":"10.1016\/j.msard.2020.102281_bib0003","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","article-title":"Multiple Sclerosis: mechanisms and immunotherapy","volume":"97","author":"Baecher-Allan","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.msard.2020.102281_bib0004","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3389\/fnins.2019.01026","article-title":"Cerebrospinal Fluid and Blood Cytokines as Biomarkers for Multiple Sclerosis: a Systematic Review and Meta-Analysis of 226 Studies With 13,526 Multiple Sclerosis Patients","volume":"13","author":"Bai","year":"2019","journal-title":"Front. Neurosci."},{"issue":"8","key":"10.1016\/j.msard.2020.102281_bib0005","doi-asserted-by":"crossref","first-page":"e11986","DOI":"10.1371\/journal.pone.0011986","article-title":"The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS)","volume":"5","author":"Brettschneider","year":"2010","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.msard.2020.102281_bib0006","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1084\/jem.20181216","article-title":"Type I interferon induces CXCL13 to support ectopic germinal center formation","volume":"216","author":"Denton","year":"2019","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.msard.2020.102281_bib0007","doi-asserted-by":"crossref","first-page":"e81007","DOI":"10.1371\/journal.pone.0081007","article-title":"Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis","volume":"8","author":"Edwards","year":"2013","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.msard.2020.102281_bib0008","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1177\/1352458509107017","article-title":"Serum levels of CXCL13 are elevated in active multiple sclerosis","volume":"15","author":"Festa","year":"2009","journal-title":"Multip. Sclero. J."},{"key":"10.1016\/j.msard.2020.102281_bib0009","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1742-2094-11-103","article-title":"CXCL13 and neopterin concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroinflammation","volume":"11","author":"Hytonen","year":"2014","journal-title":"J. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2020.102281_bib0010","doi-asserted-by":"crossref","DOI":"10.4172\/2155-9899.1000460","article-title":"Regulated Production of CXCL13 within the Central Nervous System","volume":"7","author":"Irani","year":"2016","journal-title":"J. Clin. Cell Immunol."},{"key":"10.1016\/j.msard.2020.102281_bib0011","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jns.2017.06.048","article-title":"CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis","volume":"380","author":"Iwanowski","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102281_bib0012","first-page":"335","volume":"17","author":"Khademi","year":"2011"},{"issue":"Pt 1","key":"10.1016\/j.msard.2020.102281_bib0013","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/brain\/awh680","article-title":"Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment","volume":"129","author":"Krumbholz","year":"2006","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.msard.2020.102281_bib0014","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41590-018-0135-x","article-title":"Reassessing B cell contributions in multiple sclerosis","volume":"19","author":"Li","year":"2018","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.msard.2020.102281_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219987","article-title":"Utility of chemokines CCL2, CXCL8, 10 and 13 and interleukin 6 in the pediatric cohort for the recognition of neuroinflammation and in the context of traditional cerebrospinal fluid neuroinflammatory biomarkers","volume":"14","author":"Liba","year":"2019","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.msard.2020.102281_bib0016","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ana.25197","article-title":"Inflammatory intrathecal profiles and cortical damage in multiple sclerosis","volume":"83","author":"Magliozzi","year":"2018","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2020.102281_bib0017","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ttbdis.2018.04.008","article-title":"CXCL13 concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other neurological disorders determined by Luminex and ELISA","volume":"9","author":"Markowicz","year":"2018","journal-title":"Ticks Tick. Borne Dis."},{"issue":"6","key":"10.1016\/j.msard.2020.102281_bib0018","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.autrev.2017.04.010","article-title":"Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review","volume":"16","author":"Merkel","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"10.1016\/j.msard.2020.102281_bib0019","doi-asserted-by":"crossref","first-page":"e77163","DOI":"10.1371\/journal.pone.0077163","article-title":"Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis","volume":"8","author":"Modvig","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2020.102281_bib0020","doi-asserted-by":"crossref","unstructured":"Modvig, S., Degn, M., Roed, H., Sorensen, T.L., Larsson, H.B., Langkilde, A.R., Frederiksen, J.L., Sellebjerg, F., 2015. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Multiple sclerosis (Houndmills, Basingstoke, England) 21(14), 1761\u20131770.","DOI":"10.1177\/1352458515574148"},{"issue":"2","key":"10.1016\/j.msard.2020.102281_bib0021","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/jnc.13881","article-title":"Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis","volume":"141","author":"Novakova","year":"2017","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.msard.2020.102281_bib0022","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12974-019-1440-5","article-title":"Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study","volume":"16","author":"Olesen","year":"2019","journal-title":"J. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.msard.2020.102281_bib0023","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/archneurol.2010.99","article-title":"Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis","volume":"67","author":"Piccio","year":"2010","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2020.102281_bib0024","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12987-020-0170-5","article-title":"Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction","volume":"17","author":"Pilz","year":"2020","journal-title":"Fluids Barriers CNS"},{"issue":"2","key":"10.1016\/j.msard.2020.102281_bib0025","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2020.102281_bib0026","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-510X(00)00501-3","article-title":"Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs","volume":"184","author":"Reiber","year":"2001","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2020.102281_bib0027","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12974-017-0948-9","article-title":"Cerebrospinal fluid CXCL13 as a diagnostic marker of neuroborreliosis in children: a retrospective case-control study","volume":"14","author":"Remy","year":"2017","journal-title":"J. Neuroinflamm."},{"issue":"23","key":"10.1016\/j.msard.2020.102281_bib0028","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1182\/blood-2013-01-476333","article-title":"CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma","volume":"121","author":"Rubenstein","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.msard.2020.102281_bib0029","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00115-014-4020-z","article-title":"[CXCL13: a biomarker for acute Lyme neuroborreliosis: investigation of the predictive value in the clinical routine]","volume":"85","author":"Rupprecht","year":"2014","journal-title":"Nervenarzt"},{"key":"10.1016\/j.msard.2020.102281_bib0030","first-page":"1893","volume":"23","author":"Soelberg","year":"2017"},{"issue":"3","key":"10.1016\/j.msard.2020.102281_bib0031","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/WCO.000000000000563","article-title":"B cells in multiple sclerosis","volume":"31","author":"Sospedra","year":"2018","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"10.1016\/j.msard.2020.102281_bib0032","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820303576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820303576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:49:28Z","timestamp":1761900568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820303576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":32,"alternative-id":["S2211034820303576"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102281","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102281"}}